Breast Cancer Radiation Treatment Time Shortened
What is Tamoxifen?
Tamoxifen (Nolvadex®) is a medication that reduces and/or stops the effects of estrogen (a female hormone) in the body.
It was developed over 20 years ago and has been used to treat both advanced and early stage breast cancer.
More recently, tamoxifen is being used as an adjuvant, or additional, therapy following primary treatment for early stage breast cancer.
Tamoxifen is taken by mouth in tablet form and is usually prescribed as a single daily dose.
As a breast cancer therapy, tamoxifen works against the effects of estrogen, which has been shown to promote the growth of breast cancer cells. It is often called an "anti-estrogen."
As a treatment for breast cancer, the medication slows or stops the growth of cancer cells that are already present in the body.
As adjuvant therapy, tamoxifen has been shown to help prevent the development and recurrence of breast cancer.
Research has shown that when tamoxifen is used as adjuvant therapy for early stage breast cancer, it not only prevents the recurrence of the original cancer but also prevents the development of new cancers in the opposite breast, in many cases.
As a preventative therapy, tamoxifen has been shown to help prevent the development of breast cancer in high-risk women.
Different women experience side effects differently. Some of the more common side effects may include:
- hot flashes and sweats
- nausea and vomiting
- loss of appetite
- weight gain
- vaginal discharge
- irregular menstrual cycles
- fatigue
- headache
- vaginal dryness
- irritation of skin around the vagina
Less common side effects may include:
- blood clots
- depression
- eye problems
- uterine cancer
- other cancers
Always consult your physician for more information. |
[August 2007] A sophisticated radiation therapy system safely allows the delivery of a higher daily dose for breast cancer patients and shortens the treatment time for women from six or seven weeks to just four, researchers say.
The research team used intensity-modulated radiation therapy, or IMRT, a system that is more accurate at targeting the radiation, say researchers reporting in the International Journal of Radiation Oncology Biology Physics.
The scientists wanted to see if treatment time could be shortened and the daily dose increased without any more ill effects than using the standard treatment.
"It's a bigger daily dose, but we feel it is more accurately and evenly distributed with IMRT," explains lead researcher Dr. Gary Freedman, a radiation oncologist at Fox Chase Cancer Center in Philadelphia.
Less Time in Therapy Easier on Women
Dr. Freedman says physicians now have more options than ever before in treating breast cancer.
"We have great evidence that lumpectomy and radiation is equal, in terms of survival and cure rate, to mastectomy," at least for women with smaller tumors, he says.
Even so, the length of treatment time can still present problems.
"There are many women who balk at the six- or seven-week treatment length because of perceived inconvenience, or they have to travel a lot every day [to get to treatment]," notes Dr. Freedman.
The length of treatment time for radiation therapy, prescribed in combination with a lumpectomy when a woman has breast cancer, is "a very hot issue right now in radiation," explains Dr. Freedman.
Some studies are looking at one-week treatment with partial-breast radiation, he says, using both external beam radiation and implanted radioactive seeds.
But this approach, says Dr. Freedman, is appropriate only for a very select group of women with the smallest of breast cancers.
"My study is meant to be more inclusive," he says.
His team, which also included physicians from the University of Pennsylvania, treated 75 women, averaging 52 years of age, with a higher than typical dose of daily radiation, and then followed them to check for side effects.
"It's not a higher total dose," stresses Dr. Freedman. In traditional six- or seven-week treatments, a total of 60 grays (a unit for absorbed radiation) or Gys are given. In the study, the total over the four weeks was 56 Gy.
The technique, not yet widespread, uses a computer-controlled X-ray accelerator to deliver very precise doses of radiation to the tumor or to specific areas within the tumor.
Dr. Freedman says this specificity minimizes radiation exposure to tissues around the tumor.
"So far, we have found that the immediate side effects of treatment were not increased over what we have seen with six or seven weeks of treatment," he says.
Radiation can cause skin toxicity and inflammation, for instance, but the four-week treatment results compared favorably with the results seen for conventional six- or seven-week treatment.
While some women did encounter skin problems, the skin toxicity resolved within six weeks of treatment. And the skin's cosmetic appearance was back to its pre-treatment look six weeks after treatment ended.
"We will follow [these patients] for five years," says Dr. Freedman says, to be sure no long-term problems result.
Final Studies to Evaluate Best Approach
While previous studies have found that women who got radiation treatment in the 1980s appear to be at higher risk of heart disease than women in the general population, Dr. Freedman says he believes IMRT will better protect the heart.
"We definitely reduced the dose received by the heart; we assume that means even less heart disease risk down the road," he emphasizes.
There is one downside, though: IMRT is not yet widely available, says Dr. Freedman.
Other experts said the study has both its strengths and its limitations.
Dr. Frank Vicini, chief of oncology at the Beaumont Cancer Institute, notes that the study had only 75 patients and needs more validation through other studies. Like Dr. Freedman, he also points out that the technology is not widely available.
More study will be done, he predicts. A radiation study group is already discussing trials, says Dr. Vicini.
There are other critical questions yet to be answered about any potential for long-term toxicity and recurrence, adds Dr. Shawna Willey, at Lombardi Comprehensive Cancer Center at Georgetown University.
"If long-term toxicity and recurrence are the same as for longer treatments, most women will opt for four weeks," she predicts.
Always consult your physician for more information.
|